Christopher Leamon

Company: Fusion Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

Targeted 225Ac Therapy for Cancer Using Small Molecule-, Peptide- & Antibody-Based Vectors 9:00 am

Considering if targeted radiotherapy is any better than targeted chemotherapy? Considering why 225Ac is an attractive payload for cancer therapy Discussing ligand diversity: What’s optimal for solid tumor therapy? Read more

day: Day One